Nipro : Announcement of Investment by Development Bank of Japan Inc. in a U.S. Subsidiary of NIPRO

NIPRO CORPORATION

March 25, 2026

NIPRO CORPORATION (Head office: Settsu, Osaka; President and Representative Director: Tsuyoshi Yamazaki) announces that Spryte Medical Holdings, LLC (Head office: Massachusetts, U.S.; hereinafter "Spryte"), a consolidated subsidiary of NIPRO, will receive an investment from the Development Bank of Japan Inc. (hereinafter "DBJ").

Spryte is developing intravascular imaging diagnostic technologies in the field of cerebrovascular medicine. As announced in our press release dated March 18, 2026, titled "Announcement of Spryte Medical, a US Affiliate of NIPRO, First Participants Enrolled in the "INSYTE" US Pivotal Trial evaluating the nOCT Imaging System during Brain Aneurysm Treatment" Spryte has commenced clinical trials targeting patients undergoing treatment for cerebral aneurysms using the world's first *1intracerebral (Neuro) OCT imaging system *2. This clinical trial received approval for an Investigational Device Exemption (IDE) *3 from the U.S. Food and Drug Administration (FDA) last November. Furthermore, this system has been designated as a Breakthrough Device by the FDA and is being developed with priority support from the FDA as a new diagnostic imaging technology for serious cerebrovascular diseases such as cerebral aneurysms.

DBJ is a government-affiliated financial institution whose mission is "Designing the Future with Financial Power." It works to promote Japan's industrial development and address social challenges to realize a sustainable society. In light of the substantial funding requirements anticipated to steadily advance clinical trials of Spryte's innovative medical devices and accelerate their development, this investment by DBJ reflects its recognition of the significant social value of globally expanding cutting-edge medical technologies originating from Japanese companies, including their contribution to enhancing the international competitiveness of Japan's healthcare industry. The investment is intended to support continued development efforts, including clinical trials, as well as initiatives toward future commercialization.

We will continue to proactively drive Spryte's technological development and commercialization while further strengthening our business foundation and expanding growth opportunities.

For more details on Spryte and nOCT technology, please visit, https://www.sprytemedical.com.

*1 Reference:

Science magazine, [May 15, 2024; published by the American Association for the Advancement of Science (AAAS)]

*2 Intracranial OCT (Neuro Optical Coherence Tomography, nOCT) imaging system:

An imaging diagnostic technology (optical coherence tomography) capable of high-precision visualization of the brain's intravascular space

*3 IDE (Investigational Device Exemption):

A U.S. FDA program that permits the conduct of clinical trials for medical device approval applications

Spryte Medical is an intravascular imaging, AI, and data company headquartered in Bedford, MA. The unique imaging and data platform is purpose-built to accelerate understanding of target diseases, facilitate the development of novel therapies, and to provide information for optimal treatment delivery for the benefit of patients worldwide.

The NIPRO Group will continue to drive technological innovation in the field of endovascular therapy and contribute to expanding treatment options for patients.